A biotech start-up based in Amsterdam has initiated operations with a new seed round financing totaling $50 million. The company, Avidicure, is set to develop multifunctional antibody therapies aimed at providing targeted cancer treatment. The funding, led by EQT Life Sciences and joined by notable investors such as Kurma Partners, BioGeneration Ventures, BOM, Curie Capital, and V-Bio Ventures, will support early preclinical research and broaden efforts to combat various tumor types. New initiatives and strategies underline a commitment to rigorous development and measured progress.
Other media sources have reported on similar antibody approaches in Europe that combine aspects of checkpoint inhibitors and ADCs. Those reports pointed to evolving trends in targeted cancer therapies, aligning with emerging interests in multifunctional drug design and engineered treatments.
Does the start-up offer promising cancer treatments?
Avidicure is advancing dual agonistic, engineered antibodies known as AVC-Boosters to target and treat cancer cells. The design integrates benefits from first-generation antibody formats and employs advanced avidity engineering. This approach enables potent immune activation with a focus on minimizing systemic toxicity, particularly in the tumor microenvironment.
Will the recent funding boost research progress?
The infusion of $50 million is intended to drive the development of Avidicure’s lead product, AVC-S-101. This TROP2-targeting antibody is being prepared for clinical evaluation in non-small cell lung cancer and other indications. The financing supports expansion of the company’s pipeline and accelerates both preclinical and clinical milestones.
The company’s leadership is headed by CEO Arthur Lahr, who emphasized the potential of the new antibody modality.
AVC-Boosters have the potential to change the treatment landscape for a wide range of cancers as first-in-class multifunctional antibody products that safely mobilize the full power of the immune system.
The advisory board, including Dr. Joern-Peter Halle, noted,
Avidicure’s multifunctional antibodies provide a novel treatment modality with a unique, differentiated mode of action. These products are well-positioned to significantly impact cancer treatment.
Senior management, with backgrounds at Crucell, Ablynx, and Kiadis, is supported by an experienced Supervisory Board drawn from major industry names. Preclinical data are expected to be shared at upcoming medical conferences, including AACR and ASCO meetings.
Rigorous evaluation of Avidicure’s platform is essential for the wider biotechnology field. The substantial seed investment may help clarify the clinical potential of multifunctional antibodies in oncology. Detailed data presentation at prominent conferences will offer further insights into efficacy and safety, guiding future research investments and clinical practices.
